Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy

Kaptan Y., SUNER KARAKÜLAH A., Tas M. N., OKSEL F., AKSU K., SAYINER A.

CLINICAL RHEUMATOLOGY, cilt.40, sa.9, ss.3783-3788, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 9
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s10067-021-05697-5
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.3783-3788
  • Anahtar Kelimeler: Hepatotoxicity, Isoniazid, TNF inhibitor, Treatment, Tuberculosis
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Introduction Although latent tuberculosis infection (LTBI) treatment is given before anti-tumor necrosis factor (TNF) treatment, tuberculosis (TB) still develops in these patients and the risk factors are not well known. Besides, there is little data on the safety of isoniazid (INH) treatment in this group of patients. This study aimed to determine the risk factors for the development of tuberculosis and the safety of LTBI in such patients.